Sipuleucel-T in prostate cancer: Indication of added benefit – Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T.
New test predicts the risk of non-hereditary breast cancer — A simple blood test is currently in development that could help predict the likelihood of a woman developing breast cancer – A simple blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, even in the absence of a high-risk BRCA1 gene mutation. This new research is published in the Genome Medicine.
Low cholesterol in immune cells slows HIV progression – Scientists at the University of Pittsburgh have identified why some HIV-infected people experience much slower disease progression, even without medication, and it has to do with cholesterol levels in specific immune cells.
MERS cases spike to 339 in Saudi Arabia — 8 new MERS deaths take Saudi toll to 102 – The Saudi health ministry announced eight new deaths from the MERS virus on Sunday taking the kingdom’s death toll from the disease to 102. The number of recorded infections in the kingdom has risen to 339, it added.